Wireframe preview

Best viewed on desktop.

This is a wireframe for review, not the finished site. The responsive (mobile) treatment comes in the design and build phase. Open this page on a screen at least 1200 px wide to see the layout as intended.

← The GRA Portfolio

RSV NewCo

Treatment for Respiratory Syncytial Virus

RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.

There are currently no effective antiviral treatments for RSV, but RSV NewCo is working to identify new antiviral compounds that could effectively treat and prevent RSV in high-risk infants and the elderly. So far, the company has identified a ribonucleoside that provides a strong starting point for a therapeutic.